Buy SS-31 in Canada: A Researcher’s Guide
SS-31 is unusual among research peptides because it targets the mitochondria directly. Also known as elamipretide, it is studied for its association with cardiolipin on the inner mitochondrial membrane and its role in cellular-energy research models. For Canadian researchers the sourcing questions are the usual ones: where to buy domestically and what to verify first.
Why researchers source SS-31 domestically
Peptides ordered across the border are routinely held or seized at customs. SS-31 (10 mg, lyophilised) ships from within Canada, third-party tested, with e-transfer and credit card accepted, same-day dispatch before 3 PM PST, and free shipping over $150.
What to check before you buy
- Purity documentation, a stated purity figure shown on the product page.
- Format, a lyophilised powder reconstituted with eau bactériostatique for research handling.
- Research-use framing, sold for laboratory research only; see our legal overview.
Where it fits
SS-31 sits within cellular-energy and mitochondrial research alongside NAD+ and MOTS-c. The full set is on the Recherche sur l'énergie cellulaire et les mitochondries page.
Frequently asked questions
Where can I buy SS-31 in Canada?
From domestic research suppliers. Vistara Labs stocks SS-31 10 mg and ships from within Canada, no customs risk.
How is SS-31 supplied?
As a lyophilised powder in a sealed vial, third-party tested, reconstituted with bacteriostatic water for research handling.
Is SS-31 legal in Canada?
It is sold for laboratory research use only. It is not sold for human use, and nothing here is medical advice.
All products discussed are for laboratory research use only and are not for human use. Nothing on this page is medical advice, and no statement about any compound is a claim of therapeutic or cosmetic benefit.
References
SS-31 (elamipretide) has a mature clinical programme. Mechanistic evidence is strong and human exposure substantial, but efficacy results are mixed and indication-dependent — including trials that missed their primary endpoints.
- Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical TrialRandomised, double-blind phase 3 trial (MMPOWER-3), 24 weeks. The primary exercise and fatigue endpoints were not met.
- A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathyRandomised crossover trial in adults with genetically confirmed primary mitochondrial myopathy.
- Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 TrialRandomised phase 2 trial; 71 patients. No significant improvement in left-ventricular end-systolic volume or ejection fraction versus placebo.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
